Showing 1 - 10 of 579
Persistent link: https://www.econbiz.de/10014314620
People's value for their own time is a key input in evaluating public policies: evaluations should account for time taken away from work or leisure as a result of policy. Using rich choice data collected from farming households in western Kenya, we show that households exhibit non-transitive...
Persistent link: https://www.econbiz.de/10013177601
People's value for their own time is a key input in evaluating public policies: evaluations should account for time taken away from work or leisure as a result of policy. Using rich choice data collected from farming households in western Kenya, we show that households exhibit non-transitive...
Persistent link: https://www.econbiz.de/10012938721
Persistent link: https://www.econbiz.de/10012813582
People’s value for their own time is a key input in evaluating public policies: evaluations should account for time taken away from work or leisure as a result of policy. Using rich choice data collected from farming households in western Kenya, we show that households exhibit non-transitive...
Persistent link: https://www.econbiz.de/10012815796
People’s value for their own time is a key input in evaluating public policies: evaluations should account for time taken away from work or leisure as a result of policy. Using rich choice data collected from farming households in western Kenya, we show that households exhibit non-transitive...
Persistent link: https://www.econbiz.de/10013305648
We study the design of randomized controlled experiments in environments where outcomes are significantly affected by unobserved effort decisions taken by the subjects(agents). While standard randomized controlled trials (RCTs) are internally consistent, the unobservability of effort provision...
Persistent link: https://www.econbiz.de/10008565083
Persistent link: https://www.econbiz.de/10012216055
Persistent link: https://www.econbiz.de/10011744083
Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations - for example, due to imprecise estimates...
Persistent link: https://www.econbiz.de/10011788784